FRIEDMAN FELLOWS
NEXT SYMPOSIUM: APRIL 21, 2017 IN CHICAGO, IL WITH THE AMERICAN SOCIETY FOR NUTRITION SCIENTIFIC SESSIONS

Scott B. Sperling, MD

Tufts Medical Center, Boston, MA
2015–present

Mentor   Dr. Lechan

Recent Work

Dr. Sperling’s formal training was at the University of Maryland after graduating summa cum laude with a BS in Biology and a minor in Philosophy from Bucknell University. At Bucknell, he received the President’s Award for Distinguished Academic Achievement and inducted into the Phi Beta Kappa Honor Society, and during medical school, he was inducted into the AOA honorary society. He was also involved in community service, volunteering for multiple organizations including Kids Helping Hopkins, assisting patient care at the Evangelical Community Hospital, working as a health information specialist for Medstar Physician partners and as a tutor. He did his Internal Medicine Residency at Brown University where he was described as an asset to their program, showing strong medical knowledge and clinical reasoning skills, supported by his outstanding United States Medical Licensing Examination (USMLE) scores for steps 1-3. He was also described as being a positive force to the residency program at Brown due to his positive attitude and ability to bring people together. Scott has been passionate about endocrinology and in particular, diabetes mellitus. He has worked in a Diabetes Mellitus Clinic ½ day each week during his Residency and his knowledge and abilities were described as even surpassing Endocrinology Fellows rotating in the clinic. One of his reference letters commented that he spent one of his vacations reading journal articles about diabetes, speaking to his absolute dedication to the field. He also worked on a research project to study the effectiveness of an outpatient insulin titration protocol in U-500 insulin treated diabetic patients.

Although he has only begun his Endocrinology Fellowship, he has adapted to his new position with ease and is doing an outstanding job. He has already given two, outstanding lectures to our group on SGLT-2 inhibitors for the treatment of diabetes mellitus and the pathophysiology behind their associated increased risk for the development of ketoacidosis in type 2 patients, and on the pathophysiology of hyperaldosteronism that showed a deep understanding of pathophysiology. He is engaged in screening a large kindred with SDHB mutations to identify associated members who may have paraganglioma and renal cell neoplasms.